Anavex Life Sciences Corp (NASDAQ:AVXL)
| 9.43 Delayed Data As of 12:00am ET |  +0.71 / +8.14%Today’s Change | 7.13 Today|||52-Week Range 31.50 | -45.62% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $661.1M |
Company Description
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Contact Information
Anavex Life Sciences Corp. 630 5th Avenue New York New York 10111 |
Employees
Shareholders
| Individual stakeholders | 3.05% |
| Mutual fund holders | 20.06% |
| Other institutional | 10.18% |
Top Executives
| Christopher U. Missling | Chairman, President, CEO & Secretary |
| Stephan Toutain | Chief Operating Officer |
| Sandra Boenisch | Chief Financial Officer & Treasurer |
| Walter E. Kaufmann | Chief Scientific Officer |
| Edward R. Hammond | Chief Medical Officer |
